Scholarlink

<p>Due to persistent airflow limitation, COPD patients frequently develop sarcopenia, creating a bidirectional worsening cycle: Diagnosis involves pulmonary function tests for COPD and consensus criteria (e.g., EWGSOP2) for sarcopenia. COPD promotes sarcopenia through chronic inflammation, protein metabolic imbalance, oxidative stress, and hypoxia, while sarcopenia impairs immune and respiratory muscle function, accelerating pulmonary decline. Pathogenesis is complex, involving signaling pathways that regulate inflammation, protein balance, muscle fiber transformation, and mitochondrial function. Contributing factors include sarcopenic obesity, malnutrition, hormonal disorders, corticosteroid use, and inactivity. Treatment focuses on smoking cessation, pharmacotherapy, nutritional support, and resistance exercise, with acupuncture showing potential. Current research is preliminary, with mechanisms unclear and no specific therapies available. Early diagnosis and personalized multidisciplinary interventions are crucial to disrupt the COPD-sarcopenia cycle, delay disease progression, and enhance physical function and quality of life. Therefore, this review summarizes how skeletal muscle metabolism participates in the pathophysiological processes of COPD and potential therapeutic agents for sarcopenia, aiming to provide beneficial recommendations for the clinical prevention and treatment of sarcopenia in COPD patients from a complex mechanistic perspective.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current status of research on muscle wasting associated with chronic obstructive pulmonary disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Huanhuan Zhang,
  • Zhangbo Song,
  • Qi Guo,
  • Haiyi Nie,
  • Hongdou Hou,
  • Ning Yao,
  • Sichao Dai,
  • Chengcai Yun,
  • Qihong Zhuo,
  • Yangyang Li,
  • Liying Zhang,
  • Wenxing Yong

摘要

Due to persistent airflow limitation, COPD patients frequently develop sarcopenia, creating a bidirectional worsening cycle: Diagnosis involves pulmonary function tests for COPD and consensus criteria (e.g., EWGSOP2) for sarcopenia. COPD promotes sarcopenia through chronic inflammation, protein metabolic imbalance, oxidative stress, and hypoxia, while sarcopenia impairs immune and respiratory muscle function, accelerating pulmonary decline. Pathogenesis is complex, involving signaling pathways that regulate inflammation, protein balance, muscle fiber transformation, and mitochondrial function. Contributing factors include sarcopenic obesity, malnutrition, hormonal disorders, corticosteroid use, and inactivity. Treatment focuses on smoking cessation, pharmacotherapy, nutritional support, and resistance exercise, with acupuncture showing potential. Current research is preliminary, with mechanisms unclear and no specific therapies available. Early diagnosis and personalized multidisciplinary interventions are crucial to disrupt the COPD-sarcopenia cycle, delay disease progression, and enhance physical function and quality of life. Therefore, this review summarizes how skeletal muscle metabolism participates in the pathophysiological processes of COPD and potential therapeutic agents for sarcopenia, aiming to provide beneficial recommendations for the clinical prevention and treatment of sarcopenia in COPD patients from a complex mechanistic perspective.